[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644106":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":39,"collaborators":19,"id":41,"slug":19,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":19,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":19,"overallStatus":23,"whyStopped":19,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"All participants","All participants will get ptau217 measurements.",[12],"Diagnostic Test: ptau217",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","ptau217","Quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human K2EDTA plasma.",[9],null,[21],{"facility":22,"status":23,"city":24,"state":19,"zip":25,"country":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"UZ Leuven\u002FKU Leuven","RECRUITING","Leuven","3000","Belgium",{"type":28,"coordinates":29},"Point",[30,31],4.70093,50.87959,{"lat":31,"lon":30},[34],{"name":35,"role":36,"phone":37,"phoneExt":19,"email":38},"Serafien D'hooge, MD","CONTACT","+32 16 33 86 31","serafien.dhooge@kuleuven.be",{"type":40,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100644106",false,"NCT07666113","Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.","The Diagnostic Validity and Clinical Impact of Blood-based Biomarkers for the Diagnosis of Alzheimer's Disease at the Primary Care Level.","ADPriK","Inclusion Criteria:\n\n* Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status.\n\nExclusion Criteria:\n\n* Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure).\n* Concomitant medications that would interfere with cognitive assessments.\n* A prior diagnosis of AD and related disorders or other neurodegenerative disease.",true,"ALL","55 Years","85 Years",{"count":53,"type":54},240,"ESTIMATED","INTERVENTIONAL",[57],"NA","The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217\u002FAβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns.\n\nParticipants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.",[60],"Alzheimer's Disease (AD)","2026-06-17",{"date":63,"type":64},"2026-06-24","ACTUAL",{"date":66,"type":64},"2026-05-26",{"date":68,"type":54},"2038-04",{"name":5,"class":6},1]